-
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)
The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality
DNA Assembly Cloning(Page) TA Cloning(Page) Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Lot-zu-Lot-Variabilität: Wann Sie neue Chargen wirklich prüfen müssen(Post)Lot-zu-Lot-Variabilität: Wann Sie neue Chargen wirklich prüfen müssen Ja, Lot-zu-Lot-Variabilität ist ein reales analytisches Risiko und keine theoretische Fußnote in einem Qualitätshandbuch. Prüfen
Mit 20–30 Blankreplikaten: LoD/LoQ korrekt berechnen für Ihr Labor(Post)Mit 20–30 Blankreplikaten: LoD/LoQ korrekt berechnen für Ihr Labor LoB, LoD und LoQ bilden eine feste Rangordnung: LoB ≤ LoD ≤ LoQ. LoD beantwortet die Frage „Ist die Substanz überhaupt nachweisbar?“
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons
Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword(Post)Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword In the intricate world of cancer biology, some of our body's most potent defense mechanisms can paradoxically turn against us. Cell
TIGIT, DNAM-1 and the CD155 Axis: Pathway, Function and Assays(Post)CD155 is read by four different receptors, and only one of them turns the killing programme on. The nectin and nectin-like ligands induced on stressed and transformed cells are simultaneously an acti
Galectin Therapeutics(Post)Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a chronic, irreversible and ultimately fatal disease characterized by prog
Non-Alcoholic Fatty Liver Disease (NAFLD) - Biomarkers(Post)Key Points Non-alcoholic fatty liver disease (NAFLD) refe
Antibiotic Resistance: The Growing Threat to Human Health(Post)Antibiotic resistance is a growing problem in the world today. Antibiotics are becoming less and less effective as bacteria evolve to resist them. This poses a serious threat to human healt
Ianalumab: Exploring Its Mechanism, Clinical Applications, and Research Potential(Post)Quick Facts About IanalumabWhat is Ianalumab?Ianalumab is a monoclonal antibody currently being investigated for its potential in treating autoimmune diseases, particularly lupus and imm
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Fezakinumab: Exploring Its Mechanism and Clinical Potential(Post)Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m